L
Leila R. Martins
Researcher at Instituto de Medicina Molecular
Publications - 20
Citations - 1247
Leila R. Martins is an academic researcher from Instituto de Medicina Molecular. The author has contributed to research in topics: Leukemia & PI3K/AKT/mTOR pathway. The author has an hindex of 13, co-authored 17 publications receiving 1128 citations. Previous affiliations of Leila R. Martins include German Cancer Research Center & University of Lisbon.
Papers
More filters
Journal ArticleDOI
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.
Ana Elisa Bauer de Camargo Silva,J. Andrés Yunes,Bruno A. Cardoso,Leila R. Martins,Patrícia Y. Jotta,Miguel Abecasis,Alexandre E. Nowill,Nick R. Leslie,Angelo A. Cardoso,João T. Barata +9 more
TL;DR: Overall, the data indicate that T-ALL cells inactivate PTEN mostly in a nondeletional, posttranslational manner, and Pharmacological manipulation of these mechanisms may open new avenues for T-all treatment.
Journal ArticleDOI
Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis.
Inês Sofia Vala,Leila R. Martins,Natsuko Imaizumi,Raquel J. Nunes,José Pedro Rino,François Kuonen,Lara Carvalho,Curzio Rüegg,Isabel Monteiro Grillo,João T. Barata,Marc Mareel,Susana Constantino Rosa Santos +11 more
TL;DR: It is shown that low-dose IR promotes tumor growth and metastasis and that these effects were prevented by the administration of a VEGF receptor-tyrosine kinase inhibitor immediately before IR exposure, demonstrating a new mechanism to the understanding of the potential pro-metastatic effect of IR.
Journal ArticleDOI
IL-7 Contributes to the Progression of Human T-cell Acute Lymphoblastic Leukemias
Ana Elisa Bauer de Camargo Silva,Angelo Brunelli Albertoni Laranjeira,Leila R. Martins,Bruno A. Cardoso,Jocelyne Demengeot,J. Andrés Yunes,Benedict Seddon,João T. Barata +7 more
TL;DR: It is established that interleukin-7 contributes to the progression of human T-cell leukemia, and the results offer preclinical validation of the concept that targeting IL-7/IL-7R signaling in the tumor microenvironment could elicit therapeutic effects in T-ALL.
Journal ArticleDOI
Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels
A. Margarida Gomes,Maria V. D. Soares,Patrícia Ribeiro,Joana Caldas,Vanda Póvoa,Leila R. Martins,Alice Melão,Ana Serra-Caetano,Aida Botelho de Sousa,João F. Lacerda,João T. Barata +10 more
TL;DR: It is found that adult B-cell acute lymphoblastic leukemia samples show significantly higher CK2 kinase activity and lower PTEN lipid phosphatase activity than healthy controls, and it is suggested that CK2 inhibition may constitute a valid, novel therapeutic tool in this malignancy.
Journal ArticleDOI
Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia
Leila R. Martins,Paulo Lúcio,Alice Melão,I Antunes,Bruno A. Cardoso,R Stansfield,Maria Teresa Sabrina Bertilaccio,Paolo Ghia,D Drygin,Maria Gomes da Silva,João T. Barata +10 more
TL;DR: Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia is inhibited by a second substance called CK2A, which is cytotoxic to lymphocytes and excites the immune system to attack these cells.